Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica

Page 1 of about 41 results

ea0051cme4 | CME Training Day Abstracts | BSPED2017

Thyrotoxicosis – diagnosis and management

Cheetham Tim

Key discussion points• Make sure you know what it is that you are treating – is this Graves’ hyperthyroidism (with associated TSH receptor antibodies) or simply a brief, hyperthyroid phase of autoimmune thyroid disease (without TSH receptor antibodies) that will settle down spontaneously?• Ideally obtain the result of the thyroid receptor antibody titre pre intervention with carbimazole.&#...
0 shares

ea0066in1.1 | (1) | BSPED2019

Cheetham Tim

Tim Cheetham is a University Reader and Honorary Consultant Paediatrician based in Newcastle-upon-Tyne, England, UK. He was appointed in 1996 following paediatric / endocrine / diabetes training in Oxford and Cambridge – and following 6 months as a neonatal consultant at Addenbrooke’s. He has a broad range of interests and has a key role in a number of clinical trials and studies in the field of clinical endocrinology including Graves’ disease, longer term outco...
0 shares

ea0030s6 | CME TRAINING DAY | BSPED2012

Hyperthyroidism and its management

Cheetham Tim

Thyrotoxicosis is uncommon in young people with a UK incidence around 1/100 000 (<15 years). Most cases of persistent thyroid hormone excess are due to Graves’ disease although transient episodes are seen in Hashimoto’s thyroiditis. Thyroid peroxidase antibodies can frequently be identified in both forms of autoimmune thyroid disease with antibodies to the TSH receptor more typical of Graves’. Patients with Graves’ are usually managed initially with the...
0 shares

ea0033p3 | (1) | BSPED2013

Diagnosing congenital adrenal hyperplasia. Radiologist rather than biochemist.

Schenk Daniel , Cheetham Tim

Introduction: The male child with congenital adrenal hyperplasia (CAH) due to 21 hydroxylase deficiency classically presents with salt-wasting and the female with genital ambiguity. 17-OHP measurement is a key investigation but the assay takes time to perform and is not usually available at weekends. We have examined the role of renal/adrenal ultrasonography in the above clinical scenarios.Method: An abdominal ultrasound focussing on adrenal anatomy was ...
0 shares

ea0027oc1.3 | Oral Communications 1 | BSPED2011

High likelihood of malignancy in patients presenting with a thyroid nodule

Jamil Furrukh , Cheetham Tim

Introduction: Thyroid nodules in children are more often malignant than in adult practice (~26 vs 5–10%) and in our locality the incidence of thyroid cancer in young people is increasing. We therefore assessed the presentation, investigation, histology and management of paediatric patients presenting with thyroid nodules.Methods: This was a retrospective audit conducted at a regional unit (catchment population ~3 million) where young people are like...
0 shares

ea0039oc2.2 | Oral Communications 2 | BSPED2015

Inguinal hernia repair in a girl, a missed opportunity to diagnose 17β-HSD

Jamil Syed Furrukh , Cheetham Tim

17β-hydroxysteroid dehydrogenase deficiency (17β-HSD) is a rare autosomal recessive disorder of sexual development affecting testosterone biosynthesis. Affected individual typically present with genital ambiguity at birth, inguinal gonads or excessive virilisation at puberty in a phenotypic female.Case: We present a case of a 14-year-old girl who was referred by the GP because of concerns about upper lip hair growth and deepening of her voice. ...
0 shares

ea0082wd5 | Workshop D: Disorders of the adrenal gland | SFEEU2022

Optimising the biochemical control in a young patient with classical Congenital Adrenal Hyperplasia (CAH) and history of azoospermia, resulted in spermatogenesis

Ali Mudassir , Cheetham Tim , Mitchell Anna

A male with classical salt-wasting congenital adrenal hyperplasia (CAH; 21-hydroxylase deficiency) who was diagnosed in infancy and had normal pubertal growth and development attended the endocrine department for routine follow up in June 2019 (age 26). His current daily medications are hydrocortisone 10 mg on waking, 5 mg at 4 pm and fludrocortisone 200 mg once daily. He also has injectable hydrocortisone sodium phosphate 100mg for emergency use. Over recent years, he reports...
0 shares

ea0039ep119 | Thyroid | BSPED2015

Auditing the congenital hypothyroidism (CHT) screening programme in the North East and Cumbria region

Boal Rachel , Cheetham Tim , Bartlet Kim

Introduction: UK Screening for CHT was introduced in 1981 to facilitate early detection, treatment and prevent associated morbidity and mortality. Screening in the North East and Cumbria is coordinated by the XXXXXX. A locally defined threshold of TSH >6 mU/l constitutes a positive screening test in contrast to national guidance of > 10 mU/l. We explored the longer-term outcomes of infants identified by the screening programme.Aim: The aims of th...
0 shares

ea0030oc1.7 | Oral Communications 1 | BSPED2012

Novel therapies herald novel diseases: The first paediatric case series of Graves' immune reconstitution disease

Sinha Akash , Abinun Mario , Cheetham Tim

Introduction: The use of haematopoietic stem cell transplantation (HSCT) as a curative therapy for life threatening immunodeficiency signalled a paradigm shift in clinical outcomes. However, a subset of patients may experience Thyroid Immune Reconstitution Inflammatory Syndrome (IRIS) following immune reconstitution. This is recognised in the adult population but has received little attention in the paediatric literature. We present, what we believe to be, the first case serie...
0 shares

ea0027p14 | (1) | BSPED2011

Height outcome in children with testotoxicosis

Flowers Josephine , Cheetham Tim , Johnstone Helen

Introduction: Testotoxicosis and other causes of precocious puberty can result in compromised final adult height and various treatments have been used in an attempt to address this. We report final height data in children with testotoxicosis who were treated with a variety of regimens and who have attained/are predicted to attain, a final height in excess of the mid-parental target.Patients and methods: Growth data from four patients with activating muta...
0 shares

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more